Johanna Mercier serves as Gilead’s Chief Commercial Officer, overseeing the global commercialization of the company’s medicines across virology, oncology and inflammation. She has been central to Gilead’s portfolio diversification, strengthening the company’s long-term growth prospects, expanding patient access and shaping commercial strategy.
Johanna led the swift launch and global access strategy of Gilead’s COVID-19 antiviral on an accelerated timeline during the height of the COVID-19 pandemic, while also driving Gilead’s response to the crisis, including product donations. Today, she leads efforts to establish a new investigational product as a long-acting option for HIV prevention, and to expand access for people in high-incidence, resource-limited countries through innovative launch preparations and voluntary licensing agreements.
A passionate advocate for the future of transformational healthcare and improving patient access on a global scale, Johanna serves on the boards of Neurocrine Biosciences, Arcus Biosciences and the University of Southern California’s Leonard D. Schaeffer Center for Health Policy and Economics.
Prior to joining Gilead in 2019, Johanna spent 25 years at Bristol Myers Squibb, where she held senior leadership roles across the U.S. and international markets. She received her bachelor’s degree in biology from the University of Montreal and her MBA from Concordia University.
View All Leaders